James Feusner, MD
Oakland Magazine Best East Bay Doctors 2007
(nat'l survery)
Medical Director, Oncology Program, Division of Hematology/Oncology
Clinical Scientist, Children's Hospital Oakland Research Institute (CHORI)
Medical School: University of Washington, School of Medicine, Seattle
Residency: Children's Orthopedic Hospital and Medical Center, Seattle
Fellowship: Children's Orthopedic Hospital, Seattle
Board Certification: Pediatrics, Pediatrics Hematology/Oncology
Language(s): English
News Room
Physician profile
Summary
James Feusner, MD is an expert in pediatric oncology, with particular expertise in acute promyelocytic leukemia (APL), a kind of cancer in which abnormal white blood cells replace normal blood cells in the bone marrow and surrounding blood. Dr. Feusner can discuss subjects dealing with oncology, such as tumor growth, babies with increased risk of developing tumors and supportive care to improve the quality of life for patients with cancer.
Compelling Fact
Every year, approximately 8,600 children are diagnosed with cancer in the United States and 1,500 children die from the disease. There are 12 major types of childhood cancer, but different types of leukemia, brain and other central nervous system tumors account for more than half of all new cases.
Source: National Cancer Institute
www.cancer.gov/newscenter/tip-sheet-childhood-cancers
Expertise
- Acute promyelocytic leukemia (APL)
- Acute myeloid leukemia (AML)
- Live tumors in childhood/hepatoblastoma
- Wilms tumor
Acute Promyelocytic Leukemia (APL)
Acute promyelocytic leukemia (APL) is a subtype of the acute myeloid leukemia (AML) cancer. APL is characterized by abnormal, heavily granulated promyelocytes, a form of white blood cells. APL results in the accumulation of these atypical promyelocytes in the bone marrow and peripheral blood supply, and replaces normal blood cells. APL can have serious bleeding complications at diagnosis and during early phases of treatment
Professional and Personal background
You can reach this physician by contacting Media Relations.
Email pageLearn More
